Report generated with Calculate by QxMD at https://www.qxmd.com/calculate
Over 400 decision support tools available • get the app for iOS or Android at qx.md/calculate
The CPSS-Mol is a new CMML-specific prognostic scoring system (CPSS) that incorporates molecular genetic data resulting in a 4-level integrated clinical/pathological/genetic risk stratification tool. This tool was derived from a cohort of European patients, 93% of whom possessed 1 of 38 somatic mutations. Based on multivariable Cox regression analyses, cytogenetic abnormalities and mutations in RUNX1, NRAS, SETBP1, and ASXL1 were independently associated with overall survival (OS). The CPSS-Mol fully retained its ability to risk stratify survival in an independent validation cohort of CMML patients.
Citations
Elena C, Galli A, Such E, et al.
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Blood 2016;128(10):1408-1417
Contributed By: